Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000507
UniProt IDQ96S94
Primary gene name(s)CCNL2
Synonym gene name(s)unknown
Protein nameCyclin-L2
Protein functionInvolved in pre-mRNA splicing. May induce cell death, possibly by acting on the transcription and RNA processing of apoptosis-related factors. {ECO:0000269|PubMed:14684736, ECO:0000269|PubMed:18216018}.
Subcellular locationNucleus speckle {ECO:0000269|PubMed:14684736, ECO:0000269|PubMed:18216018}. Nucleus, nucleoplasm {ECO:0000269|PubMed:18216018}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q96S94
Gene Ontology
(Biological Process)
Complete annatation
positive regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0045737];
positive regulation of phosphorylation of RNA polymerase II C-terminal domain [GO:1901409];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
transcription, DNA-templated [GO:0006351]
Gene Ontology
(Molecular Function)
Complete annatation
cyclin-dependent protein serine/threonine kinase regulator activity [GO:0016538]
Gene Ontology
(Cellular Component)
Complete annatation
cyclin-dependent protein kinase holoenzyme complex [GO:0000307];
intracellular membrane-bounded organelle [GO:0043231];
nuclear speck [GO:0016607];
nucleoplasm [GO:0005654];
nucleus [GO:0005634]
Protein-protein interaction123566
Phylogenetic treeQ96S94
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.4849042146722610.1402467654579280.230211201152461
AZA vs. DISU0.01673329305717780.9471368534906730.996198528027442
AZA vs. IL7-0.3245244451689670.09097546483893320.818499940102868
AZA vs. SAHA0.02407726875406680.9211899828108320.982071981797342
DISU vs. CD30.4884001275758120.1792289939927930.293258389039309
DISU vs. IL7-0.3507410645438840.1634818316638650.525029529683163
DISU vs. SAHA0.009901658129655370.9728437304071340.99539181670255
DMSO vs. AZA0.05057576664956740.7618570644220751
DMSO vs. CD30.5233241257168950.1028721433671720.174799102168559
DMSO vs. DISU0.03199047097508190.8954385115069140.988283279918411
DMSO vs. IL7-0.3677955598660870.04049751437272110.408764355963649
DMSO vs. SAHA-0.03177223177373310.8925645598650730.974245912143042
HIV vs. Mock in Activation0.1717966989516150.7822271067665030.999983755607037
HIV vs. Mock in Latency0.1969259216220780.2320733789778650.999834320637052
IL7 vs. CD30.1660539169533120.6052924265415260.721427824021236
SAHA vs. CD30.4855969946523430.1714754738928120.26803603273153
SAHA vs. IL70.3458271646287880.1554216224450990.373954594850348
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.461435 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category